" class="no-js "lang="en-US"> GoodCell - Medtech Alert
Saturday, October 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
GoodCell | Pharmtech Focus

GoodCell

About GoodCell

GoodCell

Founded in 2016, GoodCell’s mission is to empower people to live longer, healthier lives by using their own blood for dynamic and comprehensive diagnostics, and ultimately life-saving cell therapies. We are comprised of a team cutting-edge scientists, experienced doctors and innovative entrepreneurs whose vision is to shape the future of personalized health as today’s science becomes tomorrow’s medicine. Find out more about the truth within you by visiting our website www.goodcell.com.

Related Story

Appointments

 GoodCell Appoints Chris Garcia as New CEO | Pharmtech Focus

GoodCell Appoints Chris Garcia as New CEO

September 2 2021

GoodCell, a medically-actionable health technology service to proactively identify, track and address health risks, today […]